Collegium Pharmaceutical, Inc. COLL
22.53
(0.11)
(0.49%)
as of 25 Sep
- Market cap
- $737.1M
- P/E
- 14.7×
Follow COLL
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
22.96% | 23.70% | 27.41% | 17.61% | |
| 3.60% | 3.79% | 4.57% | 2.57% | ||
ROIC |
12.62% | 15.94% | 17.52% | 7.85% | |
Return on Tangible Assets |
33.75% | 23.87% | 23.25% | 166.34% | |
Average Days of Receivables |
112.79 | 98.82 | 104.85 | 128.76 | |
Free Cash Flow per Share |
9.16 | 10.33 | 10.28 | 10.11 | |
Free Cash Flow |
289.30 | 327.58 | 329.83 | 328.28 | |
Capital Expenditures |
(1.62) | (1.74) | (1.21) | (1.64) | |
Piotroski F-Score |
6.00 | 6.00 | 8.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
20.95% | 21.70% | 21.26% | 21.25% | |
Accounts Receivable Turnover |
3.27 | 3.55 | 3.48 | 3.25 | |
Accounts Payable Turnover |
60.04 | 43.49 | 25.38 | 32.10 | |
Inventory Turnover |
8.51 | 8.30 | 7.83 | 4.27 | |
Average Days of Payables |
8.62 | 12.26 | 7.96 | 10.44 | |
Days of Inventory on Hand |
42.88 | 47.06 | 49.82 | 127.95 | |
Tax Rate |
(0.28) | (0.32) | (0.31) | (0.38) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
37.02% | 36.49% | 37.01% | 40.54% | |
Share Based Compensation of Revenue |
5.25% | 5.37% | 5.18% | 5.56% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
4.98 | 5.24 | 4.42 | 6.89 | |
Depreciation/Fixed assets |
18.37 | 18.73 | 19.25 | 21.86 | |
Capex/Depreciation |
(0.01) | (0.01) | (0.01) | (0.01) | |
Revenue per Share |
23.98 | 24.62 | 24.82 | 24.90 | |
Operating CF per Share |
9.21 | 10.39 | 10.32 | 10.16 | |
Capex per Share |
(0.05) | (0.05) | (0.04) | (0.05) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
7.72% | 8.05% | 9.41% | 5.93% |
Columns are period end dates